A Phase 2 Study of Nivolumab in Advanced Leiomyosarcoma of the Uterus
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Leiomyosarcoma; Uterine cancer
- Focus Therapeutic Use
- 05 Jun 2017 Status changed from suspended to recruiting.
- 25 Apr 2017 Results published in the Cancer
- 19 Apr 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jan 2018.